Berlex, Premier in new MRI contrast deal
Schering AG of Germany's US subsidiary, Berlex, has been awarded a new contract to provide contrast media for magnetic resonance imaging to members of the Premier network, a strategic health care alliance entirely owned by more than 200 of the USA's leading hospital and health care systems. These systems operate or are affiliated with nearly 1,500 hospital facilities and hundreds of other health care sites.
The new contract extends the nearly decade-long relationship between the two companies. Under the terms of the agreement, Berlex will provide Premier members access to Magnevist (gadopentetate dimeglumine) Injection, the leading contrast media for enhanced MRI. The value of the contract is estimated to be in excess of $40.0 million annually.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze